Cargando…

Association of tumour and stroma PD-1, PD-L1, CD3, CD4 and CD8 expression with DCB and OS to nivolumab treatment in NSCLC patients pre-treated with chemotherapy

BACKGROUND: Immune checkpoint inhibitors are most beneficial in patients with high tumour PD-L1 expression. However, the use of PD-L1 expression is not straightforward. We investigated PD-L1 expression and immune cell (IC) infiltrates in non-small-cell lung cancer (NSCLC) patients treated with nivol...

Descripción completa

Detalles Bibliográficos
Autores principales:	Niemeijer, Anna-Larissa Nadia, Sahba, Sara, Smit, Egbert Frederik, Lissenberg-Witte, Birgit Ilja, de Langen, Adrianus Johannes, Thunnissen, Erik
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7403301/ https://www.ncbi.nlm.nih.gov/pubmed/32433601 http://dx.doi.org/10.1038/s41416-020-0888-5

Ejemplares similares

High PD-1 expression on regulatory and effector T-cells in lung cancer draining lymph nodes
por: van de Ven, Rieneke, et al.
Publicado: (2017)

CD8(+)PD-1(+) to CD4(+)PD-1(+) ratio (PERLS) is associated with prognosis of patients with advanced NSCLC treated with PD-(L)1 blockers
por: Duchemann, Boris, et al.
Publicado: (2022)

Early response evaluation of PD-1 blockade in NSCLC patients through FDG-PET-CT and T cell profiling of tumor-draining lymph nodes
por: Borm, Frank J., et al.
Publicado: (2023)

Deciphering Microenvironment of NSCLC based on CD8+ TIL Density and PD-1/PD-L1 Expression
por: Lin, Ziying, et al.
Publicado: (2019)

Prognostic value, localization and correlation of PD-1/PD-L1, CD8 and FOXP3 with the desmoplastic stroma in pancreatic ductal adenocarcinoma
por: Diana, Angela, et al.
Publicado: (2016)

PD-1 blockade potentiates neoadjuvant chemotherapy in NSCLC via increasing CD127(+) and KLRG1(+) CD8 T cells
por: Hui, Zhenzhen, et al.
Publicado: (2023)

PD-1(+) IFN-γ(+) subset of CD8(+) T cell in circulation predicts response to anti–PD-1 therapy in NSCLC
por: Chen, Wenxiu, et al.
Publicado: (2023)

IFN-γ down-regulates the PD-1 expression and assist nivolumab in PD-1-blockade effect on CD8+ T-lymphocytes in pancreatic cancer
por: Ding, Guoping, et al.
Publicado: (2019)

MDSC subtypes and CD39 expression on CD8(+) T cells predict the efficacy of anti‐PD‐1 immunotherapy in patients with advanced NSCLC
por: Koh, Jiae, et al.
Publicado: (2020)

Predictive Value of Soluble PD-1, PD-L1, VEGFA, CD40 Ligand and CD44 for Nivolumab Therapy in Advanced Non-Small Cell Lung Cancer: A Case-Control Study
por: Tiako Meyo, Manuela, et al.
Publicado: (2020)

Decreased blood CD4+PD-1+ and CD8+PD-1+ T cells in psoriatic patients with and without arthritis
por: Bartosińska, Joanna, et al.
Publicado: (2018)

Circulating memory PD-1(+)CD8(+) T cells and PD-1(+)CD8(+)T/PD-1(+)CD4(+)T cell ratio predict response and outcome to immunotherapy in advanced gastric cancer patients
por: Liu, Jiang, et al.
Publicado: (2023)

Trastuzumab and paclitaxel in patients with EGFR mutated NSCLC that express HER2 after progression on EGFR TKI treatment
por: de Langen, Adrianus J., et al.
Publicado: (2018)

Accumulation of CD5(+)CD19(+) B lymphocytes expressing PD-1 and PD-1L in hypertrophied pharyngeal tonsils
por: Wlasiuk, Paulina, et al.
Publicado: (2015)

CD72/CD100 and PD-1/PD-L1 markers are increased on T and B cells in HIV-1(+) viremic individuals, and CD72/CD100 axis is correlated with T-cell exhaustion
por: Correa-Rocha, Rafael, et al.
Publicado: (2018)

Variable density of CD8+ and CD25+ programmed cell death-1 (PD-1) ligand (PD-L1) CD4+ T cells within the tumor microenvironment causes differential responses to the PD-1/PD-L1 blockade
por: Wu, Si-Pei, et al.
Publicado: (2015)

Concordance of PD-L1 expression and CD8(+) TIL intensity between NSCLC and synchronous brain metastases
por: Batur, Sebnem, et al.
Publicado: (2020)

PD-1 blockade restores helper activity of tumor-infiltrating, exhausted PD-1(hi)CD39(+) CD4 T cells
por: Balança, Camille-Charlotte, et al.
Publicado: (2021)

Peripheral CD8+CD28+ T lymphocytes predict the efficacy and safety of PD-1/PD-L1 inhibitors in cancer patients
por: Geng, Ruixuan, et al.
Publicado: (2023)

Circulating Exhausted PD-1(+)CD39(+) Helper CD4 T Cells Are Tumor-Antigen-Specific and Predict Response to PD-1/PD-L1 Axis Blockade
por: Martinez-Gomez, Carlos, et al.
Publicado: (2022)

Systemic CD4 Immunity and PD-L1/PD-1 Blockade Immunotherapy
por: Escors, David, et al.
Publicado: (2022)

Staphylococcus aureus convert neonatal conventional CD4(+) T cells into FOXP3(+) CD25(+) CD127(low) T cells via the PD-1/PD-L1 axis
por: Rabe, Hardis, et al.
Publicado: (2014)

Anti–PD-L1 and anti-CD73 combination therapy promotes T cell response to EGFR-mutated NSCLC
por: Tu, Eric, et al.
Publicado: (2022)

Tumor mutational load, CD8(+) T cells, expression of PD-L1 and HLA class I to guide immunotherapy decisions in NSCLC patients
por: Hurkmans, Daan P., et al.
Publicado: (2020)

CD160-Associated CD8 T-Cell Functional Impairment Is Independent of PD-1 Expression
por: Viganò, Selena, et al.
Publicado: (2014)

The identification and functional analysis of CD8+PD-1+CD161+ T cells in hepatocellular carcinoma
por: Li, Zhixuan, et al.
Publicado: (2020)

Intratumoral CD103+ CD8+ T cells predict response to PD-L1 blockade
por: Banchereau, Romain, et al.
Publicado: (2021)

CD39(+)PD-1(+)CD8(+) T cells mediate metastatic dormancy in breast cancer
por: Tallón de Lara, Paulino, et al.
Publicado: (2021)

CD80 Expressed by CD8(+) T Cells Contributes to PD-L1-Induced Apoptosis of Activated CD8(+) T Cells
por: Rollins, Meagan R., et al.
Publicado: (2017)

Clinical significance of CD38 and CD101 expression in PD-1(+)CD8(+) T cells in patients with epithelial ovarian cancer
por: Zhou, Jian, et al.
Publicado: (2020)

BCL9 regulates CD226 and CD96 checkpoints in CD8(+) T cells to improve PD-1 response in cancer
por: Feng, Mei, et al.
Publicado: (2021)

CD8+CD122+PD-1+ Tregs Synergize With Costimulatory Blockade of CD40/CD154, but Not B7/CD28, to Prolong Murine Allograft Survival
por: Liu, Huazhen, et al.
Publicado: (2019)

Brain metastasis PD-L1 and CD8 expression is dependent on primary tumor type and its PD-L1 and CD8 status
por: Camy, Florian, et al.
Publicado: (2020)

Different Induction of PD-L1 (CD274) and PD-1 (CD279) Expression in THP-1-Differentiated Types 1 and 2 Macrophages
por: Lai, Chun-Yi, et al.
Publicado: (2021)

PD-1(+)CD8(+) T Cells Proximal to PD-L1(+)CD68(+) Macrophages Are Associated with Poor Prognosis in Pancreatic Ductal Adenocarcinoma Patients
por: Yang, Xiaobao, et al.
Publicado: (2023)

CD28/PD1 co-expression: dual impact on CD8(+) T cells in peripheral blood and tumor tissue, and its significance in NSCLC patients' survival and ICB response
por: Palermo, Belinda, et al.
Publicado: (2023)

CD40 Activation Rescues Antiviral CD8(+) T Cells from PD-1-Mediated Exhaustion
por: Isogawa, Masanori, et al.
Publicado: (2013)

Reduced Expression of PD-1 in Circulating CD4+ and CD8+ Tregs Is an Early Feature of RRMS
por: Machcińska, Maja, et al.
Publicado: (2022)

Adsorption sites and diffusion steps of In and Cd on Pd(111) surfaces
por: Hunger, E, et al.
Publicado: (1990)

Expression of PD-1 by CD4(+)CD25(+)CD127(low) Treg cells in the peripheral blood of lung cancer patients
por: Zhong, AnYuan, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_4pi5hgji4oflghklegv1dfffga